IMPORTANT NOTE: You may submit your article only through our online submission systemSubmit your manuscript
  • Slider Image

Reviews 2005-2017

Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review. A.K.A. KARAGIANNIS, C. GIRIO-FRAGKOULAKIS, T. NAKOUTI (Athens, Greece; Nottingham, UK).  Anticancer Res 36:3803-3810,2016.
Immunotherapy in Acute Leukemias: Implications and Perspectives Using Wt1 Antigen. G.C.M. CEBINELLI, N.D.S. PEREIRA, M.M. SENA, C.E.C. DE OLIVEIRA, T.C. FUJITA, S.P.D. DA ROCHA, F.J.D.A. OLIVEIRA, P.C. MARINELLO, M.A.E. WATANABE (Londrina-Paraná, Brazil). Anticancer Res 36:3795-3802,2016.
The Role of FOXP3 in Human Cancers. Ł. SZYLBERG, D. KARBOWNIK, A. MARSZAŁEK (Torun; Poznan, Poland). Anticancer Res 36:3789-3794,2016.
Non-routine Tracers for PET Imaging of High-grade Glioma. G. FROSINA (Genoa, Italy). Anticancer Res 36:3253-3260,2016.
The Use of Complementary and Alternative Medicine in Scandinavia: A Review Article. J. NILSSON, M. KÄLLMAN, U. ÖSTLUND, G. HOLGERSSON, M. BERGQVIST, S. BERGSTRÖM (Gavle; Umea, Sweden). Anticancer Res 36:3243-3251,2016.
Current Status of Biological Therapies for the Treatment of Metastatic Melanoma. T. TANG, R. ELDABAJE, L. YANG (San Francisco, CA, USA). Anticancer Res 36:3229-3241,2016.
Sphingosine Kinase Inhibitors as Maintenance Therapy of Glioblastoma After Ceramide-Induced Response. L.A. SORDILLO, P.P. SORDILLO, L. HELSON (Quakertown, PA, USA). Anticancer Res 36:2085-2095,2016.
The NFĸB Signaling Pathway in Papillomavirus-induced Lesions: Friend or Foe? R.M. GIL DA COSTA, M.M.S.M. BASTOS, R. MEDEIROS, P.A. OLIVEIRA (Porto; Vila Real, Portugal). Anticancer Res 36:2073-2083,2016.
Methods to Increase Future Liver Remnant Volume in Patients with Primarily Unresectable Colorectal Liver Metastases: Current State and Future Perspectives. V. TRESKA (Pilsen, Czech Republic). Anticancer Res 36:2065-2071,2016.
PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research. A. GADDUCCI, M.E. GUERRIERI (Pisa, Italy). Anticancer Res 36:2055-2064,2016.
Refining the Performance of Sentinel Lymph Node Biopsy Postneoadjuvant Chemotherapy in Patients with Pathologically Proven Pre-treatment Node-positive Breast Cancer: An Update for Clinical Practice. H.E.H. CHEHADE, H. HEADON, A. KASEM, K. MOKBEL (London, UK). Anticancer Res 36:1461-1471,2016.
From Inflammation to Cancer in Inflammatory Bowel Disease: Molecular Perspectives. M. ROMANO, F. DE FRANCESCO, L. ZARANTONELLO, C. RUFFOLO, G.A. FERRARO, G. ZANUS, A. GIORDANO, N. BASSI, U. CILLO (Padua; Naples; Treviso; Siena, Italy; Philadelphia, PA, USA). Anticancer Res 36:1447-1460,2016.
Extracorporeal Photopheresis for Non-skin GvHD. J. BITTENBRING, J. REICHRATH (Homburg, Germany). Anticancer Res 36:1395-1396,2016.
Light - Instead of UV Protection: New Requirements for Skin Cancer Prevention. L. ZASTROW, J. LADEMANN (Berlin, Germany). Anticancer Res 36:1389-1393,2016.
Vitamin D and Mortality. S. PILZ, M. GRÜBLER, M. GAKSCH, V. SCHWETZ, C. TRUMMER, B.Ó. HARTAIGH, N. VERHEYEN, A. TOMASCHITZ, W. MÄRZ (Graz; Bad Aussee, Austria; Amsterdam, the Netherlands; Bern, Switzerland; New York, NY; New Haven, CT, USA; Mannheim, Germany). Anticancer Res 36:1379-1387,2016.
Photocarcinogenesis and Skin Cancer Prevention Strategies. C. SEEBODE, J. LEHMANN, S. EMMERT (Rostock; Goettingen, Germany). Anticancer Res 36:1371-1378,2016.
Roles of Solar UVB and Vitamin D in Reducing Cancer Risk and Increasing Survival. W.B. GRANT (San Francisco, CA, USA). Anticancer Res 36:1357-1370,2016.
Tumour–Endothelial Cell Communications: Important and Indispensable Mediators of Tumour Angiogenesis. B.M. LOPES-BASTOS, W.G. JIANG, J. CAI (Cardiff, UK). Anticancer Res 36:1119-1126,2016.
Update on Biomarkers in Development of Anti-angiogenic Drugs in Gastric Cancer. S. JIA, J. CAI (Cardiff, UK; Beijing, PR China). Anticancer Res 36:1111-1118,2016.
Phosphoinositide-3-Kinase Enhancers, PIKEs: Their Biological Functions and Roles in Cancer. W. JIA, Y. FENG, A.J. SANDERS, E.L. DAVIES, W.G. JIANG (Cardiff, UK; Guangzhou, PR China). Anticancer Res 36:1103-1109,2016.
Biomarkers in Colorectal Cancer. A.J. YIU, C.Y. YIU (London, UK). Anticancer Res 36:1093-1102,2016.
Anticancer Properties of Capsaicin Against Human Cancer. R. CLARK, S.-H. LEE (College Park, MD, USA). Anticancer Res 36:837-843,2016.
Human Papillomavirus as a Diagnostic and Prognostic Tool in Cancer of Unknown Primary in the Head and Neck Region. L. SIVARS, E. TANI, A. NÄSMAN, T. RAMQVIST, E. MUNCK-WIKLAND, T. DALIANIS (Stockholm, Sweden). Anticancer Res 36:487-493. 2016.
TAS-102 an Emerging Oral Fluoropyrimidine. J. CHEN, M. HAN, M.W. SAIF (St. Lucia; Wollongong, Australia; Boston, MA, USA). Anticancer Res 36:21-26. 2016.
Factors Affecting Survival in Patients with Lung Metastases from Colorectal Cancer. A Short Meta-analysis. F. LUMACHI, G.B. CHIARA, R. TOZZOLI, A. DEL CONTEA, S.M.M. BASSO (Padova; Pordenone, Italy). Anticancer Res 36:13-19. 2016.
Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis. A. DEVINE, L. MARIGNOL (Dublin, Ireland). Anticancer Res 36:5-12. 2016.
Using Epigenetic Therapy to Overcome Chemotherapy Resistance. J. STRAUSS, W.D. FIGG (Bethesda, MD, USA). Anticancer Res 36:1-4. 2016.
Innovative Therapeutic Strategies in the Treatment of Meningioma. G. CARUSO, S.K. ELBABAA, P. GONZALEZ-LOPEZ, V. BARRESI, M. PASSALACQUA, M. CAFFO (Messina, Italy; Saint Louis, MO, USA; Alicante, Spain). Anticancer Res 35: 6391-6400. 2015
Extracellular Vesicles as Biomarkers and Therapeutic Targets in Breast Cancer. L. SADOVSKA, J. EGLĪTIS, A. LINĒ (Riga, Latvia). Anticancer Res 35: 6379-6390. 2015
Curcumin for the Treatment of Glioblastoma. L.A. SORDILLO, P.P. SORDILLO, L. HELSON (Quakertown PA, USA). Anticancer Res 35: 6373-6378. 2015
Increased Production of Lysozyme Associated with Bacterial Proliferation in Barrett’s Esophagitis, Chronic Gastritis, Gluten-induced Atrophic Duodenitis (Celiac Disease), Lymphocytic Colitis, Collagenous Colitis, Ulcerative Colitis and Crohn’s Colitis. C.A. RUBIO (Stockholm, Sweden). Anticancer Res 35: 6365-6372. 2015
Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. J. PINILLA- IBARZ, K. SWEET, J. EMOLE, M. FRADLEY (Tampa, FL, USA). Anticancer Res 35: 6355-6364. 2015
Primary Breast Cancer with Synchronous Metastatic Disease – Indications for Local Radiotherapy to the Breast and Chest Wall. S. JANSSEN, D. RADES (Hannover; Lubeck, Germany). Anticancer Res 35: 5807-5812. 2015
Brain Metastases in NSCLC – Are TKIs Changing the Treatment Strategy? W.C.M. DEMPKE, K. EDVARDSEN, S. LU, N. REINMUTH, M. RECK, A. INOUE (Cambridge, UK; Munich; Grosshansdorf, Germany; Shanghai, PR China; Sendai, Japan). Anticancer Res 35: 5797-5806. 2015
Relationship Between Metabolic Reprogramming and Mitochondrial Activity in Cancer Cells. Understanding the Anticancer Effect of Metformin and Its Clinical Implications. M. CAZZANIGA, B. BONANNI (Milan, Italy). Anticancer Res 35: 5789-5796. 2015
Natural Products That Target Cancer Stem Cells. J. MOSELHY, S. SRINIVASAN, M.K. ANKEM, C. DAMODARAN (Louisville, KY, USA). Anticancer Res 35: 5773-5788. 2015
Therapeutic Potential of Thalidomide and Its Analogues in the Treatment of Cancer. G.V. SHERBET (Huntington Beach, CA, USA; Newcastle, UK). Anticancer Res 35: 5767-5772. 2015
Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST? I. HOMPLAND, Ø.S. BRULAND (Oslo, Norway). Anticancer Res 35: 5759-5765. 2015
Immunotherapies for NSCLC: Are We Cutting the Gordian Helix? W.C.M. DEMPKE, L. SELLMANN, K. FENCHEL, K. EDVARDSEN (Munich; Mönchengladbach; Hamburg, Germany; Cambridge, UK). Anticancer Res 35: 5745-5757. 2015
Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future. M. STOTZ, A. GERGER, J. HAYBAECK, T. KIESSLICH, M.D. BULLOCK, M. PICHLER (Graz; Salzburg, Austria; Houston, TX, USA). Anticancer Res 35: 5737-5744. 2015
Atypical Fibroxanthoma - Histological Diagnosis, Immunohistochemical Markers and Concepts of Therapy. M. KOCH, A.J. FREUNDL, A. AGAIMY, F. KIESEWETTER, J. KÜNZEL, I. CICHA, C. ALEXIOU (Erlangen; Mainz, Germany). Anticancer Res 35: 5717-5735. 2015
Primary Thyroid Sarcoma: A Systematic Review. A. SUROV, S. GOTTSCHLING, A. WIENKE, H. JONAS MEYER, R.P. SPIELMANN, H. DRALLE (Halle-Wittenberg; Leipzig, Germany). Anticancer Res 35: 5185-5191. 2015
Predictive and Prognostic Value of the Tau Protein in Breast Cancer. C. BONNEAU, Z.A. GURARD-LEVIN, F. ANDRE, L. PUSZTAI, R. ROUZIER (Versailles; Paris, France; New Haven, CT, USA). Anticancer Res 35: 5179-5184. 2015
Hypofractionated Radiotherapy for Localized Prostate Cancer: A Challenging Accelerated Hypofractionated Radiotherapy. H. YAMAZAKI, S. NAKAMURA, G. SUZUKI, K. YOSHIDA, Y. YOSHIOKA, M. KOIZUMI, K. OGAWA (Kyoto; Takatsuki City; Suita, Japan). Anticancer Res 35: 5167-5177. 2015
Chronic Lymphocytic Leukemia: Current Concepts. E.-M. YU, A. KITTAI, I.A. TABBARA (Washington, DC, USA). Anticancer Res 35: 5149-5165. 2015
Nitric Oxide and Aggressive Behavior of Lung Cancer Cells. S. LUANPITPONG, P. CHANVORACHOTE (Bangkok, Thailand). Anticancer Res 35: 4585-4592. 2015
Second-line Treatment of Advanced Gastric Cancer: Current Options and Future Perspectives. P. CHROM, R. STEC, C. SZCZYLIK (Warsaw, Poland). Anticancer Res 35: 4575-4583. 2015
The Role of Methylation in Breast Cancer Susceptibility and Treatment. M.-C. POULIOT, Y. LABRIE, C. DIORIO, F. DUROCHER (Quebec, Canada). Anticancer Res 35: 4569-4574. 2015
Novel Molecular Targets for the Therapy of Urothelial Cancer. B.R.P. JANA, Y. ZHOU (Galveston, TX, USA). Anticancer Res 35: 4557-4567. 2015
Transcriptional Regulation of the p16 Tumor Suppressor Gene. Y. KOTAKE, M. NAEMURA, C. MURASAKI, Y. INOUE, H. OKAMOTO (Fukuoka, Japan). Anticancer Res 35: 4397-4401. 2015
Page: 1 2 3 4 5 6 ... 7 8 9 10 11 
Custom Tables Plugin 05a1a29bdcae7b12229e651a9fd48b11

IMPORTANT NOTE: You may submit your article only through our online submission system